The protective effect of total flavonoids of cortex mori on airway inflammation in asthmatic mice
GE Shuyu1, LI Lan2, SUN Pingping1
1.Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310005, China; 2.Department of Respiratory, the First Affiliated Hospital of Zhejiang University of Traditional Chinese Medicine, Hangzhou 310006, China
GE Shuyu,LI Lan,SUN Pingping1. The protective effect of total flavonoids of cortex mori on airway inflammation in asthmatic mice[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2020, 50(7): 535-540.
Abstract：Objective: To investigate the protective effect of total flavonoid of cortex mori (TFCM) on airway inflammation in asthmatic mice and its mechanism. Methods: C57BL/6 mice were randomly divided into normal group, model group, groups of low, medium and high dose TFCM and dexamethasone positive control group. Abnormal groups were sensitized and induced with ovalbumin (OVA). TFCM (50, 100, 200 mg/kg) was administered to each dose group while the positive control group was given dexamethasone (0.5 mg/kg). The normal group and the model group were given the same amount of saline. The mice were placed in an animal lung function testing system to measure lung resistance and lung compliance. Bronchoalveolar lavage fluid (BALF) and blood samples of the mice were collected to determine IL-4, IL-5, IL-13, Eotaxin, IgE, mucin MUC5AC, MUC5B levels and total cell count, white blood cell differential counts. Airway inflammation was observed by HE and AB-PAS staining in lung tissues. Results: Compared with the model group, lung resistance was significantly increased in all dose groups of TFCM, and lung compliance was significantly decreased (P<0.05). The number of total cells, neutrophils, eosinophils and macrophages in BALF in the middle and high dose groups of TFCM were significantly lower than those in the model group (P<0.05). The levels of IL-4 and IgE in BALF in the middle and high dose groups were significantly lower than those in the model group (P<0.05). The IL-5 level in the high dose group was significantly lower than that in the model group (P<0.05). The levels of IL-13, Eotaxin, MUC5AC and MUC5B in each dose groups of TFCM were significantly lower than those in the model group (P<0.05). The HE and AB-PAS staining results showed that the airway inflammation of the lung tissue of the TFCM dose group was significantly reduced compared with the model group. Conclusion: TFCM can reduce the airway inflammation and have a significant effect on asthma in mice.
